Please assess the completion status of the following clinical trial:

Trial Title: LDL-Cholesterol Lowering Effect of KB2115 as Add on to Statin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Males or females aged 18 to 75 years. Female patients must be non-fertile. To be considered as non-fertile, females must fulfil the following:~   * Non-nursing and non-pregnant 12 months prior to enrolment~  * Not of child bearing potential ie, either documented irreversible surgically sterile (bilateral oophorectomy or hysterectomy is acceptable, but not tubal ligation) or post-menopausal. Post-menopausal is defined as serum follicle-stimulating hormone (FSH) levels in the post-menopausal range combined with amenorrhea for more than 1 year in a woman above 50 years of age, or amenorrhea for more than 2 years below 50 years of age~3. Patients with hypercholesterolemia treated with stable doses of the below listed lipid lowering medication for at least 3 months prior to randomization~   * Atorvastatin not more than 20 mg/day or~  * Simvastatin not more than 40 mg/day~4. LDL-cholesterol \> 3.0 mmol/L (Week -1)~5. Subject able and willing to comply with all study requirements~6. At randomization, diet as instructed by the investigator during the last 4 weeks prior to randomization and willingness to follow these instructions throughout the study~Exclusion Criteria:~1. Cholesterol lowering agents other than the defined statins~2. History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study as judged by the investigator~3. Clinically significant illness or clinically relevant trauma within 2 weeks before the administration of the investigational product as judged by the investigator~4. Chronic (\> 3 months) pain condition requiring daily medication with pain killers~5. Glycosylated haemoglobin (HbA1c) \> 7.0%~6. Diabetes requiring medication other than metformin~7. Clinically abnormal physical findings and laboratory values as judged by the investigator and abnormal resting ECG, eg, QTc interval \> 450 msec~8. Body Mass Index of ≥ 40 kg/m2~9. Resent history (\< 3 month) of stroke or transient ischemic attacks~10. History of seizure disorder, except febrile convulsions~11. A current diagnosis of cancer, unless in remission~12. Blood pressure (BP) of \> 160/95 mm Hg~13. History of cardiac arrhythmia, such as intermittent supraventricular tachyarrhythmia and atrial fibrillation~14. Unstable angina pectoris, myocardial infarction or coronary bypass graft surgery or percutaneous coronary intervention \< 6 month before randomization~15. Congestive heart failure New York Heart Association Class \> 2~16. Unstable or severe angina pectoris or peripheral artery disease~17. Known thyroid disease or thyroid biomarkers (TSH, T3, free T3, T4, free T4) outside reference range for normal at enrolment and at baseline~18. Positive urine pregnancy test in women at enrolment~19. Use of thyroid replacement therapy and hormone replacement therapy (including contraceptive pills) for last 3 months before randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Statin + placebo
- 2 (Type: EXPERIMENTAL): Statin + KB2115 dose 1
- 3 (Type: EXPERIMENTAL): Statin + KB2115 dose 2
- 4 (Type: EXPERIMENTAL): Statin + KB2115 dose 3

Based on this trial design, predict the completion outcome and termination type (if applicable).